Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio
Rhea-AI Summary
Jyong Biotech (Nasdaq: MENS) advanced market access strategies for botanical drugs Botreso® and PCP, citing clinical efficacy, safety, and competitive manufacturing barriers.
Botreso completed four Phase III trials (one-year dosing); PCP completed a two-year Phase II with 702 subjects and 135 urologists. Reported metabolic benefits include triglyceride and cholesterol improvements (P≤0.05). Both candidates remain investigational and are not approved for commercial use.
Positive
- Botreso completed four Phase III clinical trials (one-year dosing)
- PCP Phase II: 702 subjects across 20 hospitals and 135 urologists over two years
- Reported metabolic improvements: triglycerides (P=0.05), lower total cholesterol and LDL (P<0.05), higher HDL (P<0.05)
- Global patent protection and signed letters of intent with international pharmaceutical companies
Negative
- Both Botreso and PCP remain investigational and have not received regulatory approval
- PCP Phase II results are described as a trend toward reduced prostate cancer incidence, not definitive proof of prevention
- Market-value claims rely on on-patent pricing assumptions; current treatment market figures are reduced by patent expirations
News Market Reaction – MENS
In the Apr 28 session, MENS gained 0.93%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 27 | Drug benefits update | Positive | -4.0% | Update on clinical and IP highlights for plant-derived drug MCS‑2. |
| Feb 12 | Phase II data | Positive | +0.7% | Phase II MCS‑8 data showing reduced prostate cancer incidence and lipid benefits. |
| Jan 30 | Biomarker analysis | Positive | -7.8% | Updated Phase II biomarker results for PCP supporting prevention and metabolic value. |
| Dec 19 | Volatility response | Neutral | -4.7% | Company response to share volatility and recap of completed clinical program. |
| Dec 04 | Partnership MOU | Positive | -0.2% | Non-binding MOU for MCS‑2 commercialization in Vietnam and prior LOI in Korea. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and partnership updates have often been met with negative short-term price reactions, suggesting a pattern of selling into good news.
Over the last six months, Jyong Biotech has repeatedly highlighted progress in its plant-derived prostate therapies, including four Phase III trials for API-1/MCS‑2 and Phase II data for MCS‑8 (PCP) with prostate cancer incidence reduction and metabolic benefits. It has also pursued regional MOUs in Asia and addressed volatility following a lock-up expiry. Despite generally constructive clinical and strategic updates, four of the last five news events saw negative 24-hour price reactions.
Key Terms
benign prostatic hyperplasia medical
bph medical
gleason score medical
ldl medical
hdl medical
phase iii medical
phase ii medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
New Taipei City, Taiwan, April 28, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it has advanced the market access strategies for its innovative plant-based drugs Botreso® and PCP, after an analysis of their clinical efficacy and competitive advantages.
As previously announced, its first core product, Botreso®, has completed four Phase III clinical trials (API-1) in the United States and Taiwan while its second core product, PCP, has successfully completed its Phase II clinical trial. Overall clinical data indicates that Jyong Biotech's innovative botanical drugs demonstrate significant differentiated advantages over currently prescribed synthetic chemical drugs.
Safety Profile for Long-Term Use
For middle-aged and elderly men requiring long-term medication, safety is one of the most decisive factor. During the clinical trials – a one-year medication period for Botreso® (Phase III) and a two-year period for PCP (Phase II) – no drug-related serious adverse events were observed, indicating excellent safety and tolerability.
In contrast, current synthetic chemical drugs for BPH treatment are frequently accompanied by side effects such as orthostatic hypotension, erectile dysfunction, and decreased libido. Regulatory and research institutions have associated some synthetic alternatives with serious risks, prompting the US FDA to issue safety announcements regarding high-grade prostate cancer and depression in 2011, and to add suicidal ideation to adverse reaction lists in 2022, alongside independent research linking them to cardiac failure in 2021.
Addressing the Risk of High-Grade Prostate Cancer
Large-scale international clinical trials have shown that while some synthetic drugs for BPH treatment reduce overall prostate cancer incidence, they may paradoxically increase the proportion of high-grade prostate cancer (Gleason Score ≥ 7) when cancer does occur, raising significant clinical safety concerns.
The PCP Phase II trial was a rare large-scale, long-term study in Taiwan, conducted across 20 major hospitals. It involved 135 urologists (representing more than one-tenth of the profession in Taiwan) and 702 subjects over a two-year period. It represents one of the world's first clinical trials of a botanical new drug conducted in Taiwan specifically for prostate cancer prevention. Results indicated that PCP shows a trend in reducing both overall prostate cancer incidence and the risk of high-grade prostate cancer, effectively addressing medical community concerns regarding the risks of current therapies.
Comprehensive "Treatment + Prevention + Metabolic Management"
Based on clinical data from the clinical trials conducted by the Company, the Company believes that it is establishing a differentiated product positioning:
- Improves Lower Urinary Tract Symptoms (LUTS): Effectively addresses symptoms associated with enlarged prostates.
- Prostate Cancer Prevention: Demonstrates preventative clinical potential.
- Metabolic and Cardiovascular Protection: Reduces triglycerides (P=0.05), significantly lowers total cholesterol and LDL (bad cholesterol) (P<0.05) , significantly increases HDL (good cholesterol) (P<0.05) , and maintains stable blood sugar.
This integrated approach provides benefits without negatively affecting blood pressure, liver function, or kidney function. The Company believes that such a comprehensive profile – combining treatment, prevention, and metabolic management – is highly uncommon among current prostate medications and holds strong appeal for men over the age of 40.
Technological Barriers and Competitive Advantages
Due to the inherent complexity and diversity of their compositions, quality control for botanical new drugs is significantly more challenging than for small-molecule chemical drugs. Jianyong Biotech believes it has successfully established a comprehensive technological platform that includes:
- The purification and establishment of reference standards.
- The development and validation of analytical methods.
- The execution of validation analyses and verification processes.
The Company believes this integrated capability creates a high barrier to entry, rendering the products highly difficult to replicate. Furthermore, it effectively mitigates the risks associated with counterfeiting and generic drug competition, which ultimately helps to extend the period of market exclusivity.
Upgraded Market Positioning and Strategic Value
As a Botanical New Drug protected by global patents, Jyong Biotech believes its market strategies leverage several key advantages:
- Pricing Power: The unique metabolic protection and safety profile allow for premium pricing over off-patent generics, making it attractive to out-of-pocket and high-end medical markets.
- Licensing Potential: The combination of high tolerability, excellent safety (no severe adverse reactions), and multiple clinical benefits makes it an ideal target for international pharmaceutical partnerships.
- Market Scalability: Extends the product scope from a treatment-oriented approach into the fields of preventative medicine and health management.
Globally, over 500 million men aged 50 and above seek treatment for Benign Prostatic Hyperplasia (BPH). The global BPH drug market, valued at
“Due to their complex composition, botanical new drugs present significant quality control challenges compared to small-molecule chemical drugs,” stated Fu-Feng Kuo, Chairwoman and CEO of Jyong Biotech. “We have established a robust technology platform encompassing the purification of standard references, the development and validation of analytical methods, and the execution of validation analysis. This high barrier to entry makes imitation difficult, mitigates generic competition, and helps extend the period of market exclusivity.”
“Botreso® is the first orally administered botanical new drug developed in Taiwan to receive US FDA Phase III clinical trial (API-1) IND approval and complete four Phase III trials,” Kuo said. “Holding multi-national invention patents across Asia, the Americas, and the EU, Jyong Biotech has signed letters of intent and investment plans with several international pharmaceutical companies. The company aims to continue expanding strategic, royalty-bearing partnerships to support its global market expansion.”
As of present day, Botreso® and PCP remain investigational new drug candidates and have not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.
*Data source: BMC Urology 2025 (Global Epidemiology); IMARC BPH market report; P&S Intelligence market data; Global Market Statistics; Grand View Research (device market); Market Analytics (drug segmentation).
About Jyong Biotech Ltd.
Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, pharmacology, toxicology, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public.
For more information, please visit: https://www.jyongbio.com/, https://jyongir.com/.
Forward-Looking Statement
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement, prospectuses, annual and interim reports, and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Jyong Biotech Ltd.
ir@jyongbio.com
Investor Relations
WFS Investor Relations Inc.
Email: services@wfsir.com
Phone: +1 628 283 9214
